Canadian-based biopharmaceutical company Immunovaccine has started dosing patients in a Phase Ib/II trial of its vaccine DPX-E7 for the treatment of incurable human papillomavirus (HPV) related oropharyngeal, cervical and anal cancers.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Stand Up To Cancer and the Farrah Fawcett Foundation has granted $1.5m to Dana-Farber Cancer Institute to carry out the trial as a part of its collaborative translational research on HPV-related cancers.

DPX-E7 is an investigational vaccine candidate that employs patented DepoVax platform and targets an HPV viral protein called E7.

The single-centre, open label, non-randomised Phase Ib/II trial is designed to evaluate the safety and clinical efficacy of DPX-E7 and low-dose metronomic oral cyclophosphamide combination in 44 subjects.

"It is also an important step forward in developing therapies for the high-risk HPV infections that have been linked to cancers associated with poor patient outcomes."

Immunovaccine chief executive officer Frederic Ors said: "Because DPX-E7 is formulated with the same DepoVax platform technology as our DPX-Survivac candidate, this trial further demonstrates the broad applicability of DepoVax to deliver cancer antigens appropriately.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

"It is also an important step forward in developing therapies for the high-risk HPV infections that have been linked to cancers associated with poor patient outcomes.

"We are pleased to be working with the Dana-Farber Cancer Institute in this endeavor, and we look forward to continuing to fully leverage our platform's potential to address high unmet medical needs, delivering more options to patients and creating more opportunities to generate value for our shareholders."

The trial's primary objective is assessment of changes in CD8+ T-cells present in peripheral blood and tumour tissue, and to determine the safety of the vaccination in HPV-related incurable head and neck, cervical or anal cancer patients who are HLA-A2 positive.

Image: Phase Ib/II trial for HPV-related cancers. Photo: courtesy of Praisaeng/FreeDigitalPhotos.net.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact